UCB, Teva, Novartis, Pfizer and TransCelerate Biopharma win industry recognition at the eyeforpharma Philadelphia Awards 2016

eyeforpharma 2 - 3 May 2016, Philadelphia, USA.
The 2016 eyeforpharma Philadelphia Awards saw 22 finalists, with representation from every top 20 pharma, showcase the breadth of innovation within the industry. Submissions displayed cutting-edge application of new strategies for old problems.

Teva won the Most Valuable HCP or Healthcare Initiative with their foray into Artificial Intelligence. Teva presented "ASK Claire", an Intelligent Virtual Health Assistant that engages Multiple sclerosis (MS) patients on the web and in an app.

UCB picked up the Most Valuable Patient Initiative or Service Award with their Report Cards submission. The team presented an intriguing approach to create new incentives for decision makers to prioritise innovative therapies for Epilepsy Patients, by creating transparency into current care outcomes.

Individual leaders were also recognized for their refusal to accept the status quo, showing the way for the industry to progress. Chrisi Shaw, the, U.S. Country Head and President of Novartis picked up the Lifetime Achievement Award for her leadership on gender equality and contributions to patient-centricity throughout the pharma lifecycle.

Pfizer's Dennis Freire was awarded for his contributions towards patient-centric clinical trials with the Customer Innovator Award. Through a collaboration with ICON Firecrest collaboration, Freire oversaw a radical re-think of the onerous procedures facing patient registrants for clinical trials.

The groundbreaking consortium of top 20 pharma TransCelerate was also recognized with the Most Valuable Pharma Collaboration award for the work they've achieved in unlocking innovation that benefits everyone in pharma. Through shared research partnerships and close regulatory coordination, they are redefining the boundaries of what is possible in cross-industry collaboration on issues of shared commercial, and patient-centric interest.

The awards reflect eyeforpharma's mission to evangelize the need for pharma to change its focus from selling products, to seeing the powerful opportunity that pharma has to impact and improve the lives of patients. The winning projects were selected from hundreds of initiatives submitted from teams across the global, and determined by a judging panel of senior industry experts, and patient advocates.

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]